GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nautilus Biotechnology Inc (NAS:NAUT) » Definitions » Interest Coverage

Nautilus Biotechnology (Nautilus Biotechnology) Interest Coverage : N/A (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nautilus Biotechnology Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Nautilus Biotechnology's Operating Income for the three months ended in Mar. 2024 was $-21.61 Mil. Nautilus Biotechnology's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Nautilus Biotechnology Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Nautilus Biotechnology's Interest Coverage or its related term are showing as below:


NAUT's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 148.11
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Nautilus Biotechnology Interest Coverage Historical Data

The historical data trend for Nautilus Biotechnology's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nautilus Biotechnology Interest Coverage Chart

Nautilus Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Interest Coverage
N/A N/A N/A N/A

Nautilus Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Nautilus Biotechnology's Interest Coverage

For the Biotechnology subindustry, Nautilus Biotechnology's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nautilus Biotechnology's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Nautilus Biotechnology's Interest Coverage falls into.



Nautilus Biotechnology Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nautilus Biotechnology's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Nautilus Biotechnology's Interest Expense was $0.00 Mil. Its Operating Income was $-76.15 Mil. And its Long-Term Debt & Capital Lease Obligation was $31.09 Mil.

GuruFocus does not calculate Nautilus Biotechnology's interest coverage with the available data.

Nautilus Biotechnology's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Nautilus Biotechnology's Interest Expense was $0.00 Mil. Its Operating Income was $-21.61 Mil. And its Long-Term Debt & Capital Lease Obligation was $29.95 Mil.

GuruFocus does not calculate Nautilus Biotechnology's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Nautilus Biotechnology  (NAS:NAUT) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Nautilus Biotechnology Interest Coverage Related Terms

Thank you for viewing the detailed overview of Nautilus Biotechnology's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Nautilus Biotechnology (Nautilus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
2701 Eastlake Avenue East, Seattle, WA, USA, 98102
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
Executives
Michael Seth Altman director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Subramanian Sankar officer: Senior VP, Product Development C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Gwen E Weld officer: Chief People Officer C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Anna Mowry officer: CFO and Treasurer C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Matthew B. Murphy officer: General Counsel C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109
Sujal M Patel director, 10 percent owner, officer: CEO, President, and Secretary C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Mary E. Godwin officer: Senior VP, Operations 3101 WESTERN AVENUE, SEATTLE WA 98121
Karen Akinsanya director SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew S Mcilwain director 1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104
Benjamin A Horowitz 10 percent owner 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Marc L Andreessen 10 percent owner C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111